Skip to main content
SpringerLink
Log in

Testicular Cancer

  • Chapter
  • First Online:
Clinical Uro-Andrology

  • 1024 Accesses

Abstract

Testicular cancer includes diverse groups of tumors, 95 % of which are germ cell tumors (GCTs). GCTs are generally categorized as seminoma and nonseminoma (NSGCT) due to differences in natural history and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aass N, Fossa SD, Theodorsen L et al (1991) Prediction of long-term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 27:1087–1091

    CAS  PubMed  Google Scholar 

  • Abratt RP, Pontin AR, Barnes RD et al (1994) Adjuvant chemotherapy for stage I non-seminomatous testicular cancer. S Afr Med J 84:605–607

    CAS  PubMed  Google Scholar 

  • Aggarwal N, Parwani AV (2009) Spermatocytic seminoma. Arch Pathol Lab Med 133:1985–1988

    PubMed  Google Scholar 

  • Akre O, Pettersson A, Richiardi L (2009) Risk of contralateral testicular cancer among men with unilaterally undescended testis: a meta-analysis. Int J Cancer 124(3):687–689

    CAS  PubMed  Google Scholar 

  • Albers P, Miller GA, Orazi A et al (1995) Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis. Cancer 75:844–850

    CAS  PubMed  Google Scholar 

  • Albers P, Bender H, Yilmaz H et al (1999) Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 53:808–811

    CAS  PubMed  Google Scholar 

  • Albers P, Ganz A, Hannig E et al (2000) Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 164:381–384

    CAS  PubMed  Google Scholar 

  • Albers P, Siener R, Kliesch S et al (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21:1505–1512

    PubMed  Google Scholar 

  • Albers P, Weissbach L, Krege S et al (2004) Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol 171:1835–1838

    PubMed  Google Scholar 

  • Albers P, Albrecht W, Algaba F et al (2005) Guidelines on testicular cancer. Eur Urol 48:885–894

    PubMed  Google Scholar 

  • Albers P, Siener R, Krege S et al (2008) Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26:2966–2972

    CAS  PubMed  Google Scholar 

  • Alexandre J, Fizazi K, Mahe C et al (2001) Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 37:576–582

    CAS  PubMed  Google Scholar 

  • Altena R, de Haas EC, Nuver J et al (2009) Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br J Cancer 100:1861–1866

    PubMed Central  CAS  PubMed  Google Scholar 

  • Amato RJ, Ro JY, Ayala AG et al (2004) Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 63:144–148; discussion 148–149

    PubMed  Google Scholar 

  • Andre F, Fizazi K, Culine S et al (2000) The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 36:1389–1394

    CAS  PubMed  Google Scholar 

  • Aparicio J, Garcia del Muro X, Maroto P et al (2003) Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14:867–872

    CAS  PubMed  Google Scholar 

  • Aparicio J, Germa JR, Garcia del Muro X et al (2005) Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23:8717–8723

    PubMed  Google Scholar 

  • Bajorin DF, Sarosdy MF, Pfister DG et al (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 11:598–606

    CAS  PubMed  Google Scholar 

  • Baniel J, Foster RS, Gonin R et al (1995) Late relapse of testicular cancer. J Clin Oncol 13:1170–1176

    CAS  PubMed  Google Scholar 

  • Beck SD, Foster RS, Bihrle R et al (2002) Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol 168:1402–1404

    PubMed  Google Scholar 

  • Beck SD, Patel MI, Sheinfeld J (2004) Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. J Urol 171:168–171

    PubMed  Google Scholar 

  • Beck SD, Foster RS, Bihrle R et al (2005) Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 23:6149–6156

    PubMed  Google Scholar 

  • Behnia M, Foster R, Einhorn LH et al (2000) Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: the Indiana University experience. Eur J Cancer 36:472–475

    CAS  PubMed  Google Scholar 

  • Beyer J, Kramar A, Mandanas R et al (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14:2638–2645

    CAS  PubMed  Google Scholar 

  • Beyer J, Stenning S, Gerl A et al (2002) High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 13:599–605

    CAS  PubMed  Google Scholar 

  • Bhayani SB, Ong A, Oh WK et al (2003) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 62:324–327

    PubMed  Google Scholar 

  • Blomberg Jensen M, Leffers H, Petersen JH et al (2008) Association of the polymorphism of the CAG repeat in the mitochondrial DNA polymerase gamma gene (POLG) with testicular germ-cell cancer. Ann Oncol 19:1910–1914

    CAS  PubMed  Google Scholar 

  • Bohlen D, Borner M, Sonntag RW et al (1999) Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161:1148–1152

    CAS  PubMed  Google Scholar 

  • Bokemeyer C, Berger CC, Kuczyk MA et al (1996a) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14:2923–2932

    CAS  PubMed  Google Scholar 

  • Bokemeyer C, Kohrmann O, Tischler J et al (1996b) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann Oncol 7:1015–1021

    CAS  PubMed  Google Scholar 

  • Bokemeyer C, Kollmannsberger C, Flechon A et al (2002a) Prognostic factors in patients (pts) with advanced metastatic seminoma (SEM) treated with either single agent carboplatin (CP) or cisplatin-based (DDP) combination chemotherapy (CTX): a meta-analysis of prospective European trials. Proc Am Soc Clin Oncol 21:740

    Google Scholar 

  • Bokemeyer C, Nichols CR, Droz JP et al (2002b) Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 20:1864–1873

    PubMed  Google Scholar 

  • Bokemeyer C, Kollmannsberger C, Stenning S et al (2004) Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer 91:683–687

    PubMed Central  CAS  PubMed  Google Scholar 

  • Bosl GJ, Vogelzang NJ, Goldman A et al (1981) Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 2:970–973

    CAS  PubMed  Google Scholar 

  • Bosl GJ, Geller NL, Bajorin D et al (1988) A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231–1238

    CAS  PubMed  Google Scholar 

  • Bosl GJ, Dmitrovsky E, Reuter VE et al (1989) Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors. J Natl Cancer Inst 81:1874–1878

    CAS  PubMed  Google Scholar 

  • Bray F, Richiardi L, Ekbom A et al (2006) Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 118(12):3099–3111

    CAS  PubMed  Google Scholar 

  • Bredael JJ, Vugrin D, Whitmore WF Jr (1982) Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer 50:548–551

    CAS  PubMed  Google Scholar 

  • Brenner DJ, Hall EJ (2007) Computed tomography—an increasing source of radiation exposure. N Engl J Med 357:2277–2284

    CAS  PubMed  Google Scholar 

  • Brenner PC, Herr HW, Morse MJ et al (1996) Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 14:1765–1769

    CAS  PubMed  Google Scholar 

  • Brydoy M, Fossa SD, Klepp O et al (2005) Paternity following treatment for testicular cancer. J Natl Cancer Inst 97:1580–1588

    PubMed  Google Scholar 

  • Brydoy M, Oldenburg J, Klepp O et al (2009) Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682–1695

    PubMed Central  PubMed  Google Scholar 

  • Burger H, Nooter K, Boersma AW et al (1998) Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Br J Cancer 77:1562–1567

    PubMed Central  CAS  PubMed  Google Scholar 

  • Calvert AH, Egorin MJ (2002) Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer 38:11–16

    CAS  PubMed  Google Scholar 

  • Carmignani L, Morabito A, Gadda F et al (2005) Prognostic parameters in adult impalpable ultrasonographic lesions of the testicle. J Urol 174:1035–1038

    PubMed  Google Scholar 

  • Carver BS, Serio AM, Bajorin D et al (2007a) Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol 25:5603–5608

    PubMed  Google Scholar 

  • Carver BS, Shayegan B, Eggener S et al (2007b) Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 25:4365–4369

    PubMed  Google Scholar 

  • Carver BS, Shayegan B, Serio A et al (2007c) Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 25:1033–1037

    PubMed  Google Scholar 

  • Castedo SM, de Jong B, Oosterhuis JW et al (1989) Chromosomal changes in human primary testicular nonseminomatous germ cell tumors. Cancer Res 49:5696–5701

    CAS  PubMed  Google Scholar 

  • Chaganti RS, Houldsworth J (2000) Genetics and biology of adult human male germ cell tumors. Cancer Res 60:1475–1482

    CAS  PubMed  Google Scholar 

  • Chamie K, Kurzrock EA, Romero V et al (2008) Increased risk of secondary malignancy in patients on surveillance for NSGCT. J Urol 179:172–173; abstract 492

    Google Scholar 

  • Cheville JC (1999) Classification and pathology of testicular germ cell and sex cord–stromal tumors. Urol Clin North Am 26:595–609

    CAS  PubMed  Google Scholar 

  • Chevreau C, Mazerolles C, Soulie M et al (2004) Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46:209–214; discussion 214–215

    CAS  PubMed  Google Scholar 

  • Choo R, Thomas G, Woo T et al (2005) Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma. Int J Radiat Oncol Biol Phys 61:736–740

    PubMed  Google Scholar 

  • Christensen TB, Daugaard G, Geertsen PF et al (1998) Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 9:657–660

    CAS  PubMed  Google Scholar 

  • Chung P, Parker C, Panzarella T et al (2002) Surveillance in stage I testicular seminoma—risk of late relapse. Can J Urol 9:1637–1640

    CAS  PubMed  Google Scholar 

  • Chung PW, Warde PR, Panzarella T et al (2003) Appropriate radiation volume for stage IIA/B testicular seminoma. Int J Radiat Oncol Biol Phys 56:746–748

    PubMed  Google Scholar 

  • Chung PW, Bayley AJ, Sweet J et al (2004a) Spermatocytic seminoma: a review. Eur Urol 45:495–498

    PubMed  Google Scholar 

  • Chung PW, Gospodarowicz MK, Panzarella T et al (2004b) Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 45:754–759; discussion 759–760

    PubMed  Google Scholar 

  • Classen J, Dieckmann K, Bamberg M et al (2003a) Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer 88:828–831

    PubMed Central  CAS  PubMed  Google Scholar 

  • Classen J, Schmidberger H, Meisner C et al (2003b) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21:1101–1106

    PubMed  Google Scholar 

  • Classen J, Schmidberger H, Meisner C et al (2004) Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients: a trial of the German testicular cancer study group (GTCSG). Br J Cancer 90:2305–2311

    PubMed Central  CAS  PubMed  Google Scholar 

  • Coleman J, Brennan MF, Alektiar K et al (2003) Adult spermatic cord sarcomas: management and results. Ann Surg Oncol 10:669–675

    PubMed  Google Scholar 

  • Collette L, Sylvester RJ, Stenning SP et al (1999) Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91:839–846

    CAS  PubMed  Google Scholar 

  • Colls BM, Harvey VJ, Skelton L et al (1999) Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years’ experience in a national study in New Zealand. BJU Int 83:76–82

    CAS  PubMed  Google Scholar 

  • Comiter CV, Kibel AS, Richie JP et al (1998) Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases. J Urol 159:859–863

    CAS  PubMed  Google Scholar 

  • Connolly SS, D’Arcy FT, Gough N et al (2006) Carefully selected intratesticular lesions can be safely managed with serial ultrasonography. BJU Int 98:1005–1007; discussion 1007

    PubMed  Google Scholar 

  • Culine S, Theodore C, Terrier-Lacombe MJ et al (1996) Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol 155:1296–1298

    CAS  PubMed  Google Scholar 

  • Culine S, Theodore C, Court BH et al (1997) Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis. Br J Urol 79:258–262

    CAS  PubMed  Google Scholar 

  • Culine S, Kerbrat P, Kramar A et al (2007) Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 18:917–924

    CAS  PubMed  Google Scholar 

  • Culine S, Kramar A, Theodore C et al (2008) Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26:421–427

    CAS  PubMed  Google Scholar 

  • Cullen MH, Stenning SP, Parkinson MC et al (1996) Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14:1106–1113

    CAS  PubMed  Google Scholar 

  • Daugaard G, Petersen PM, Rorth M (2003) Surveillance in stage I testicular cancer. APMIS 111:76–83; discussion 83–85

    PubMed  Google Scholar 

  • Davis BE, Herr HW, Fair WR et al (1994) The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 152:111–113; discussion 114

    CAS  PubMed  Google Scholar 

  • De Santis M, Becherer A, Bokemeyer C et al (2004) 2–18Fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the Prospective Multicentric SEMPET Trial. J Clin Oncol 22:1034–1039

    PubMed  Google Scholar 

  • de Wit R, Stoter G, Kaye SB et al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15:1837–1843

    PubMed  Google Scholar 

  • de Wit R, Stoter G, Sleijfer DT et al (1998) Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 78:828–832

    PubMed Central  PubMed  Google Scholar 

  • de Wit R, Roberts JT, Wilkinson PM et al (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629–1640

    PubMed  Google Scholar 

  • de Wit M, Brenner W, Hartmann M et al (2008) [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 19:1619–1623

    PubMed  Google Scholar 

  • Dearnaley DP, Horwich A, A’Hern R et al (1991) Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer 27:684–691

    CAS  PubMed  Google Scholar 

  • Dearnaley DP, Fossa SD, Kaye SB et al (2005) Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br J Cancer 92:2107–2113

    PubMed Central  CAS  PubMed  Google Scholar 

  • Debono DJ, Heilman DK, Einhorn LH et al (1997) Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455–1464

    CAS  PubMed  Google Scholar 

  • DeCastro BJ, Peterson AC, Costabile RA (2008) A 5-year followup study of asymptomatic men with testicular microlithiasis. J Urol 179:1420–1423; discussion 1423

    PubMed  Google Scholar 

  • Dieckmann KP, Loy V (1996) Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 14:3126–3132

    CAS  PubMed  Google Scholar 

  • Dieckmann KP, Pichlmeier U (2004) Clinical epidemiology of testicular germ cell tumors. World J Urol 22:2–14

    PubMed  Google Scholar 

  • Dieckmann KP, Skakkebaek NE (1999) Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 83:815–822

    CAS  PubMed  Google Scholar 

  • Dieckmann KP, Bruggeboes B, Pichlmeier U et al (2000) Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 55:102–106

    CAS  PubMed  Google Scholar 

  • Dieckmann KP, Classen J, Loy V (2003) Diagnosis and management of testicular intraepithelial neoplasia (carcinoma in situ)—surgical aspects. APMIS 111:64–68; discussion 68–69

    PubMed  Google Scholar 

  • Dieckmann KP, Albers P, Classen J et al (2005) Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 173:824–829

    PubMed  Google Scholar 

  • Donadio AC, Motzer RJ, Bajorin DF et al (2003) Chemotherapy for teratoma with malignant transformation. J Clin Oncol 21:4285–4291

    CAS  PubMed  Google Scholar 

  • Donohue JP, Foster RS (1998) Retroperitoneal lymphadenectomy in staging and treatment: the development of nerve-sparing techniques. Urol Clin North Am 25:461–468

    CAS  PubMed  Google Scholar 

  • Donohue JP, Zachary JM, Maynard BR (1982) Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128:315–320

    CAS  PubMed  Google Scholar 

  • Donohue JP, Rowland RG, Kopecky K et al (1987) Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 137:1176–1179

    CAS  PubMed  Google Scholar 

  • Donohue JP, Thornhill JA, Foster RS et al (1993) Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 149:237–243

    CAS  PubMed  Google Scholar 

  • Donohue JP, Thornhill JA, Foster RS et al (1995) Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A:1599–1604

    CAS  PubMed  Google Scholar 

  • Donohue JP, Leviovitch I, Foster RS et al (1998) Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol 16:65–71

    CAS  PubMed  Google Scholar 

  • Dotan ZA, Tal R, Golijanin D et al (2006) Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol 176:2033–2038; discussion 2038–2039

    PubMed  Google Scholar 

  • Doyle DM, Einhorn LH (2008) Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys 70:1361–1364

    PubMed  Google Scholar 

  • Droz JP, Kramar A, Biron P et al (2007) Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 51:739–746; discussion 747–748

    CAS  PubMed  Google Scholar 

  • Duchesne GM, Stenning SP, Aass N et al (1997) Radiotherapy after chemotherapy for metastatic seminoma—a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 33:829–835

    CAS  PubMed  Google Scholar 

  • Duran I, Sturgeon JF, Jewett MA et al (2007) Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT). J Clin Oncol 25:240s; abstract 5021

    Google Scholar 

  • Eastham JA, Wilson TG, Russell C et al (1994) Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 43:74–80

    CAS  PubMed  Google Scholar 

  • Eble JN (1994) Spermatocytic seminoma. Hum Pathol 25:1035–1042

    CAS  PubMed  Google Scholar 

  • Eggener SE, Carver BS, Loeb S et al (2007a) Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer 109:528–535

    PubMed  Google Scholar 

  • Eggener SE, Carver BS, Sharp DS et al (2007b) Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol 177:937–943

    PubMed  Google Scholar 

  • Ehrlich Y, Brames MJ, Beck SD et al (2010) Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28:531–536

    CAS  PubMed  Google Scholar 

  • Einhorn LH (1981) Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41:3275–3280

    CAS  PubMed  Google Scholar 

  • Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8:1777–1781

    CAS  PubMed  Google Scholar 

  • Einhorn LH, Williams SD, Loehrer PJ et al (1989) Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 7:387–391

    CAS  PubMed  Google Scholar 

  • Einhorn LH, Williams SD, Chamness A et al (2007) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340–348

    CAS  PubMed  Google Scholar 

  • El Mesbahi O, Terrier-Lacombe MJ, Rebischung C et al (2007) Chemotherapy in patients with teratoma with malignant transformation. Eur Urol 51:1306–1311; discussion 1311–1312

    PubMed  Google Scholar 

  • Epstein JI (2010) The lower urinary tract and male genital system. In: Kumar V, Abbas AK, Fausto N et al (eds) Robbins and Cotran pathologic basis of disease, 8th edn. Elsevier, Philadelphia

    Google Scholar 

  • Fagundes MA, Zietman AL, Althausen AF et al (1996) The management of spermatic cord sarcoma. Cancer 77:1873–1876

    CAS  PubMed  Google Scholar 

  • Feldman DR, Bosl GJ, Sheinfeld J et al (2008) Medical treatment of advanced testicular cancer. JAMA 299:672–684

    CAS  PubMed  Google Scholar 

  • Fernandez EB, Moul JW, Foley JP et al (1994) Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 44:548–552

    CAS  PubMed  Google Scholar 

  • Feuer EJ, Frey CM, Brawley OW et al (1994) After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol 12:368–377

    CAS  PubMed  Google Scholar 

  • Fizazi K, Tjulandin S, Salvioni R et al (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an international study group. J Clin Oncol 19:2647–2657

    CAS  PubMed  Google Scholar 

  • Fizazi K, Oldenburg J, Dunant A et al (2008) Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 19:259–264

    CAS  PubMed  Google Scholar 

  • Flechon A, Bompas E, Biron P et al (2002) Management of post-chemotherapy residual masses in advanced seminoma. J Urol 168:1975–1979

    PubMed  Google Scholar 

  • Fossa SD, Aass N, Kaalhus O (1989a) Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 16:383–388

    CAS  PubMed  Google Scholar 

  • Fossa SD, Ous S, Lien HH et al (1989b) Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 141:557–559

    CAS  PubMed  Google Scholar 

  • Fossa SD, Qvist H, Stenwig AE et al (1992) Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 10:569–573

    CAS  PubMed  Google Scholar 

  • Fossa SD, Oliver RT, Stenning SP et al (1997) Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 33:1380–1387

    CAS  PubMed  Google Scholar 

  • Fossa SD, Bokemeyer C, Gerl A et al (1999a) Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 85:988–997

    CAS  PubMed  Google Scholar 

  • Fossa SD, Horwich A, Russell JM et al (1999b) Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17:1146

    CAS  PubMed  Google Scholar 

  • Fossa SD, Stenning SP, Gerl A et al (1999c) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80:1392–1399

    PubMed Central  CAS  PubMed  Google Scholar 

  • Fossa SD, Aass N, Harvei S et al (2004) Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 90:607–612

    PubMed Central  CAS  PubMed  Google Scholar 

  • Fossa SD, Chen J, Schonfeld SJ et al (2005) Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 97:1056–1066

    PubMed  Google Scholar 

  • Fossa SD, Gilbert E, Dores GM et al (2007) Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99:533–544

    PubMed  Google Scholar 

  • Fossa SD, Oldenburg J, Dahl AA (2009) Short- and long-term morbidity after treatment for testicular cancer. BJU Int 104:1418–1422

    PubMed  Google Scholar 

  • Foster RS, Baniel J, Leibovitch I et al (1996) Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. J Urol 155:1943–1945

    CAS  PubMed  Google Scholar 

  • Fox EP, Weathers TD, Williams SD et al (1993) Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11:1294–1299

    CAS  PubMed  Google Scholar 

  • Francis R, Bower M, Brunstrom G et al (2000) Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 36:1925–1932

    CAS  PubMed  Google Scholar 

  • Freedman LS, Parkinson MC, Jones WG et al (1987) Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 2:294–298

    CAS  PubMed  Google Scholar 

  • Garcia del Muro X, Maroto P, Guma J et al (2008) Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 26:5416–5421

    CAS  PubMed  Google Scholar 

  • Geldart TR, Simmonds PD, Mead GM (2002) Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int 90:451–455

    CAS  PubMed  Google Scholar 

  • Gels ME, Hoekstra HJ, Sleijfer DT et al (1995) Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 13:1188–1194

    CAS  PubMed  Google Scholar 

  • George DW, Foster RS, Hromas RA et al (2003) Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 21:113–122

    PubMed  Google Scholar 

  • Gerl A, Clemm C, Schmeller N et al (1994) Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 70:960–965

    PubMed Central  CAS  PubMed  Google Scholar 

  • Gerl A, Clemm C, Schmeller N et al (1995) Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 6:483–488

    CAS  PubMed  Google Scholar 

  • Gerl A, Clemm C, Schmeller N et al (1997) Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8:41–47

    CAS  PubMed  Google Scholar 

  • Gholam D, Fizazi K, Terrier-Lacombe MJ et al (2003) Advanced seminoma—treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients. Cancer 98:745–752

    PubMed  Google Scholar 

  • Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York

    Google Scholar 

  • Gremmer R, Schroder ML, Ten Huinink WW et al (2008) Successful management of brain metastasis from malignant germ cell tumours with standard induction chemotherapy. J Neurooncol 90:335–339

    CAS  PubMed  Google Scholar 

  • Hao D, Seidel J, Brant R et al (1998) Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance. J Urol 160:768–771

    CAS  PubMed  Google Scholar 

  • Harding MJ, Paul J, Gillis CR et al (1993) Management of malignant teratoma: does referral to a specialist unit matter? Lancet 341:999–1002

    CAS  PubMed  Google Scholar 

  • Hartmann JT, Candelaria M, Kuczyk MA et al (1997a) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33:843–847

    CAS  PubMed  Google Scholar 

  • Hartmann JT, Schmoll HJ, Kuczyk MA et al (1997b) Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 8:531–538

    CAS  PubMed  Google Scholar 

  • Hartmann JT, Bamberg M, Albers P et al (2003) Multidisciplinary treatment and prognosis of patients (pts) with central nervous system metastases (CNS) from testicular germ cell tumor (GCT) origin. Proc Am Soc Clin Oncol 22:Abst 1607

    Google Scholar 

  • Heidenreich A, Sesterhenn IA, Mostofi FK et al (1998) Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83:1002–1011

    CAS  PubMed  Google Scholar 

  • Heidenreich A, Weissbach L, Holtl W et al (2001) Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 166:2161–2165

    CAS  PubMed  Google Scholar 

  • Heidenreich A, Albers P, Hartmann M et al (2003) Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169:1710–1714

    PubMed  Google Scholar 

  • Hemminki K, Chen B (2006) Familial risks in testicular cancer as aetiological clues. Int J Androl 29:205–210

    PubMed  Google Scholar 

  • Hendry WF, Norman AR, Dearnaley DP et al (2002) Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer 94:1668–1676

    PubMed  Google Scholar 

  • Hermans BP, Sweeney CJ, Foster RS et al (2000) Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 163:1721–1724

    CAS  PubMed  Google Scholar 

  • Herr HW, Sheinfeld J, Puc HS et al (1997) Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157:860–862

    CAS  PubMed  Google Scholar 

  • Hilton S, Herr HW, Teitcher JB et al (1997) CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 169:521–525

    CAS  PubMed  Google Scholar 

  • Hindley RG, Chandra A, Saunders A et al (2003) Impalpable testis cancer. BJU Int 92:572–574

    CAS  PubMed  Google Scholar 

  • Hinton S, Catalano PJ, Einhorn LH et al (2003) Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 97:1869–1875

    CAS  PubMed  Google Scholar 

  • Hinz S, Schrader M, Kempkensteffen C et al (2008) The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol 179:936–940

    Google Scholar 

  • Holmes L Jr, Escalante C, Garrison O et al (2008) Testicular cancer incidence trends in the USA (1975–2004): plateau or shifting racial paradigm? Public Health 122:862–872

    PubMed  Google Scholar 

  • Honecker F, Wermann H, Mayer F et al (2009) Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 27:2129–2136

    CAS  PubMed  Google Scholar 

  • Horan G, Rafique A, Robson J et al (2007) CT of the chest can hinder the management of seminoma of the testis; it detects irrelevant abnormalities. Br J Cancer 96:882–885

    PubMed Central  CAS  PubMed  Google Scholar 

  • Horner MJ, Ries LAG, Krapcho M et al (2009) SEER cancer statistics review, 1975–2006. National Cancer Institute, Bethesda

    Google Scholar 

  • Horwich A, Alsanjari N, A’Hern R et al (1992) Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65:775–778

    PubMed Central  CAS  PubMed  Google Scholar 

  • Horwich A, Norman A, Fisher C et al (1994) Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. J Urol 151:72–77; discussion 77–78

    CAS  PubMed  Google Scholar 

  • Horwich A, Sleijfer DT, Fossa SD et al (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15:1844–1852

    CAS  PubMed  Google Scholar 

  • Horwich A, Oliver RT, Wilkinson PM et al (2000) A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer 83:1623–1629

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hotte S, Mayhew LA, Jewett M et al Management of stage I nonseminomatous testicular cancer: guideline recommendations. http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=140482008. Accessed 10 Nov 2010

  • Houldsworth J, Xiao H, Murty VV et al (1998) Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16:2345–2349

    CAS  PubMed  Google Scholar 

  • Howard GC, Clarke K, Elia MH et al (1995) A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists. Br J Cancer 72:1303–1306

    PubMed Central  CAS  PubMed  Google Scholar 

  • Hu GX, Lian QQ, Ge RS et al (2009) Phthalate-induced testicular dysgenesis syndrome: Leydig cell influence. Trends Endocrinol Metab 20:139–145

    PubMed Central  CAS  PubMed  Google Scholar 

  • Huddart RA, Norman A, Shahidi M et al (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513–1523

    CAS  PubMed  Google Scholar 

  • Huddart RA, O’Doherty MJ, Padhani A et al (2007) 18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22—the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 25:3090–3095

    PubMed  Google Scholar 

  • Hunt BM, Vallieres E, Buduhan G et al (2009) Sarcoidosis as a benign cause of lymphadenopathy in cancer patients. Am J Surg 197:629–632; discussion 632

    PubMed  Google Scholar 

  • Hussain SA, Ma YT, Palmer DH et al (2008) Biology of testicular germ cell tumors. Expert Rev Anticancer Ther 8:1659–1673

    PubMed  Google Scholar 

  • Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170:5–11

    PubMed  Google Scholar 

  • Huyghe E, Matsuda T, Daudin M et al (2004) Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 100:732–737

    PubMed  Google Scholar 

  • International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group (1997) J Clin Oncol 15:594–603

    Google Scholar 

  • Janetschek G, Hobisch A, Peschel R et al (2000) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol 163:1793–1796

    CAS  PubMed  Google Scholar 

  • Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

    PubMed  Google Scholar 

  • Jewett MA (1990) Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am 17:449–456

    CAS  PubMed  Google Scholar 

  • Jones WG, Fossa SD, Mead GM et al (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23:1200–1208

    PubMed  Google Scholar 

  • Joudi FN, Konety BR (2005) The impact of provider volume on outcomes from urological cancer therapy. J Urol 174:432–438

    PubMed  Google Scholar 

  • Kanetsky PA, Mitra N, Vardhanabhuti S et al (2009) Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 41:811–815

    PubMed Central  CAS  PubMed  Google Scholar 

  • Karellas ME, Damjanov I, Holzbeierlein JM (2007) ITGCN of the testis, contralateral testicular biopsy and bilateral testicular cancer. Urol Clin North Am 34:119–125; abstract vii

    PubMed  Google Scholar 

  • Kesler KA, Rieger KM, Hammoud ZT et al (2008) A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg 85:371–378

    PubMed  Google Scholar 

  • Kollmannsberger C, Nichols C, Bamberg M et al (2000) First-line high-dose chemotherapy +/−radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol 11:553–559

    CAS  PubMed  Google Scholar 

  • Kollmannsberger C, Beyer J, Bokemeyer C (2009) High-dose chemotherapy in nonseminomatous germ cell cancer. BJU Int 104:1398–1403

    CAS  PubMed  Google Scholar 

  • Kollmannsberger C, Daneshmand S, So A et al (2010a) Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 28:537–542

    PubMed  Google Scholar 

  • Kollmannsberger C, Moore C, Chi KN et al (2010b) Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 21:1296–1301

    CAS  PubMed  Google Scholar 

  • Kondagunta GV, Sheinfeld J, Mazumdar M et al (2004) Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 22:464–467

    CAS  PubMed  Google Scholar 

  • Kondagunta GV, Bacik J, Donadio A et al (2005) Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23:6549–6555

    CAS  PubMed  Google Scholar 

  • Kondagunta GV, Bacik J, Sheinfeld J et al (2007) Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 25:85–90

    CAS  PubMed  Google Scholar 

  • Krege S, Beyer J, Souchon R et al (2008a) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): I. Eur Urol 53:478–496

    PubMed  Google Scholar 

  • Krege S, Beyer J, Souchon R et al (2008b) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): II. Eur Urol 53:497–513

    PubMed  Google Scholar 

  • Lackner JE, Koller A, Schatzl G et al (2009) Androgen deficiency symptoms in testicular cancer survivors are associated with sexual problems but not with serum testosterone or therapy. Urology 74:825–829

    PubMed  Google Scholar 

  • Leibovitch L, Foster RS, Kopecky KK et al (1995) Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 154:1759–1763

    CAS  PubMed  Google Scholar 

  • Lerner SE, Mann BS, Blute ML et al (1995) Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and long-term results. Mayo Clin Proc 70:821–828

    CAS  PubMed  Google Scholar 

  • Levi JA, Raghavan D, Harvey V et al (1993) The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 11:1300–1305

    CAS  PubMed  Google Scholar 

  • Little JS Jr, Foster RS, Ulbright TM et al (1994) Unusual neoplasms detected in testis cancer patients undergoing post-chemotherapy retroperitoneal lymphadenectomy. J Urol 152:1144–1149

    PubMed  Google Scholar 

  • Liu S, Wen SW, Mao Y et al (1999) Birth cohort effects underlying the increasing testicular cancer incidence in Canada. Can J Public Health 90:176–180

    CAS  PubMed  Google Scholar 

  • Loehrer PJ Sr, Einhorn LH, Williams SD (1986) VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4:528–536

    PubMed  Google Scholar 

  • Loehrer PJ Sr, Birch R, Williams SD et al (1987) Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 5:1212–1220

    PubMed  Google Scholar 

  • Loehrer PJ Sr, Lauer R, Roth BJ et al (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540–546

    PubMed  Google Scholar 

  • Loehrer PJ Sr, Johnson D, Elson P et al (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470–476

    PubMed  Google Scholar 

  • Loehrer PJ Sr, Gonin R, Nichols CR et al (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500–2504

    CAS  PubMed  Google Scholar 

  • Logothetis CJ, Samuels ML, Trindade A et al (1982) The growing teratoma syndrome. Cancer 50:1629–1635

    CAS  PubMed  Google Scholar 

  • Logothetis CJ, Swanson DA, Dexeus F et al (1987) Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. J Clin Oncol 5:906–911

    CAS  PubMed  Google Scholar 

  • Lorch A, Kollmannsberger C, Hartmann JT et al (2007) Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 25:2778–2784

    CAS  PubMed  Google Scholar 

  • Lorch A, Beyer J, International Prognostic Factors Study Group et al (2010) Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28:4906–4911

    Google Scholar 

  • Lowrance WT, Cookson MS, Clark PE et al (2007) Assessing retroperitoneal lymphadenectomy experience in United States urological residency programs. J Urol 178:500–503; discussion 503

    PubMed  Google Scholar 

  • Lutke Holzik MF, Hoekstra HJ, Mulder NH et al (2003) Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor. Ann Surg Oncol 10:131–135

    PubMed  Google Scholar 

  • Mai PL, Chen BE, Tucker K et al (2009) Younger age-at-diagnosis for familial malignant testicular germ cell tumor. Fam Cancer 8:451–456

    PubMed Central  PubMed  Google Scholar 

  • Mardiak J, Salek T, Sycova-Mila Z et al (2005) Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study. Neoplasma 52:243–247

    PubMed  Google Scholar 

  • Martin OV, Shialis T, Lester JN et al (2008) Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. Environ Health Perspect 116:149–157

    PubMed Central  PubMed  Google Scholar 

  • Mayer F, Stoop H, Scheffer GL et al (2003) Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9:767–773

    CAS  PubMed  Google Scholar 

  • McCaffrey JA, Mazumdar M, Bajorin DF et al (1997) Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15:2559–2563

    CAS  PubMed  Google Scholar 

  • McGlynn KA, Devesa SS, Sigurdson AJ et al (2003) Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97:63–70

    PubMed  Google Scholar 

  • McGlynn KA, Devesa SS, Graubard BI et al (2005) Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol 23:5757–5761

    PubMed  Google Scholar 

  • McGuire MS, Rabbani F, Mohseni H et al (2003) The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU Int 91:469–473

    CAS  PubMed  Google Scholar 

  • McKenney JK, Heerema-McKenney A, Rouse RV (2007) Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol 14:69–92

    PubMed  Google Scholar 

  • McKiernan JM, Goluboff ET, Liberson GL et al (1999) Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol 162:361–363

    CAS  PubMed  Google Scholar 

  • McLeod DG, Weiss RB, Stablein DM et al (1991) Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 145:1178–1183; discussion 1182–1183

    CAS  PubMed  Google Scholar 

  • Mead GM, Stenning SP, Parkinson MC et al (1992) The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol 10:85–94

    CAS  PubMed  Google Scholar 

  • Mead GM, Cullen MH, Huddart R et al (2005) A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 93:178–184

    PubMed Central  CAS  PubMed  Google Scholar 

  • Mead GM, Fossa SD, Oliver RT et al (2008) Relapse patterns in 2,466 stage 1 seminoma patients (pts) entered into Medical Research Council randomised trials. J Clin Oncol 26:255s; abstract 5020

    Google Scholar 

  • Meinardi MT, Gietema JA, van der Graaf WT et al (2000) Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725–1732

    CAS  PubMed  Google Scholar 

  • Mencel PJ, Motzer RJ, Mazumdar M et al (1994) Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12:120–126

    CAS  PubMed  Google Scholar 

  • Michael H, Lucia J, Foster RS et al (2000) The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol 24:257–273

    CAS  PubMed  Google Scholar 

  • Miller KD, Loehrer PJ, Gonin R et al (1997) Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 15:1427–1431

    CAS  PubMed  Google Scholar 

  • Montgomery E, Fisher C (2003) Paratesticular liposarcoma: a clinicopathologic study. Am J Surg Pathol 27:40–47

    PubMed  Google Scholar 

  • Montironi R (2002) Intratubular germ cell neoplasia of the testis: testicular intraepithelial neoplasia. Eur Urol 41:651–654

    PubMed  Google Scholar 

  • Mosharafa AA, Foster RS, Leibovich BC et al (2003) Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 169:2126–2128

    PubMed  Google Scholar 

  • Motzer R, Bosl G, Heelan R et al (1987) Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 5:1064–1070

    CAS  PubMed  Google Scholar 

  • Motzer RJ, Amsterdam A, Prieto V et al (1998) Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 159:133–138

    CAS  PubMed  Google Scholar 

  • Motzer RJ, Bolger GB, Boston B et al (2006) Testicular cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:1038–1058

    CAS  PubMed  Google Scholar 

  • Motzer RJ, Nichols CJ, Margolin KA et al (2007) Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25:247–256

    CAS  PubMed  Google Scholar 

  • Moul JW, Paulson DF, Dodge RK et al (1990) Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol 143:520–523

    CAS  PubMed  Google Scholar 

  • Muller T, Gozzi C, Akkad T et al (2006) Management of incidental impalpable intratesticular masses of < or = 5 mm in diameter. BJU Int 98:1001–1004

    PubMed  Google Scholar 

  • Murphy BR, Breeden ES, Donohue JP et al (1993) Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11:324–329

    CAS  PubMed  Google Scholar 

  • Nelson JB, Chen RN, Bishoff JT et al (1999) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 54:1064–1067

    CAS  PubMed  Google Scholar 

  • Nguyen CT, Fu AZ, Gilligan TD et al (2010) Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. J Clin Oncol 28:119–125

    PubMed  Google Scholar 

  • Nichols CR, Catalano PJ, Crawford ED et al (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16:1287–1293

    CAS  PubMed  Google Scholar 

  • Nicolai N, Miceli R, Artusi R et al (2004) A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol 171:172–176

    PubMed  Google Scholar 

  • Nielsen ME, Lima G, Schaeffer EM et al (2007) Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer. Urology 70:1168–1172

    PubMed  Google Scholar 

  • Nonomura N, Nagahara A, Oka D et al (2009) Brain metastases from testicular germ cell tumors: a retrospective analysis. Int J Urol 16:887–893

    PubMed  Google Scholar 

  • Nord C, Bjoro T, Ellingsen D et al (2003) Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44:322–328

    PubMed  Google Scholar 

  • Nuver J, Smit AJ, Wolffenbuttel BHR et al (2005) The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer [see comment]. J Clin Oncol 23:3718–3725

    CAS  PubMed  Google Scholar 

  • Oechsle K, Hartmann M, Brenner W et al (2008) [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 26:5930–5935

    PubMed  Google Scholar 

  • Oldenburg J, Alfsen GC, Lien HH et al (2003) Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21:3310–3317

    PubMed  Google Scholar 

  • Oldenburg J, Alfsen GC, Waehre H et al (2006) Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer 94:820–827

    PubMed Central  CAS  PubMed  Google Scholar 

  • Oliver RT, Edmonds PM, Ong JY et al (1994) Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 29:3–8

    CAS  PubMed  Google Scholar 

  • Oliver RT, Ong J, Shamash J et al (2004) Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 63:556–561

    CAS  PubMed  Google Scholar 

  • Oliver RT, Mason MD, Mead GM et al (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293–300

    CAS  PubMed  Google Scholar 

  • Oliver RT, Mead GM, Fogarty PJ et al (2008) Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 26:5s; abstract 1

    Google Scholar 

  • Ondrus D, Hornak M, Matoska J et al (1992) Primary chemotherapy in the management of low stage (IIA and IIB) non-seminomatous germ cell testicular tumours. Int Urol Nephrol 24:299–304

    CAS  PubMed  Google Scholar 

  • Ondrus D, Matoska J, Belan V et al (1998) Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 33:562–566

    CAS  PubMed  Google Scholar 

  • Osada K, Iijima H, Imasawa M et al (2004) Metastatic uveal tumor secondary to testicular choriocarcinoma. Jpn J Ophthalmol 48:85–87

    PubMed  Google Scholar 

  • Patterson H, Norman AR, Mitra SS et al (2001) Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol 59:5–11

    CAS  PubMed  Google Scholar 

  • Peckham MJ, Hendry WF (1985) Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy. Br J Urol 57:763–768

    CAS  PubMed  Google Scholar 

  • Pico JL, Rosti G, Kramar A et al (2005) A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 16:1152–1159

    PubMed  Google Scholar 

  • Pizzocaro G (1987) Retroperitoneal lymph node dissection in clinical stage IIA and IIB nonseminomatous germ cell tumours of the testis. Int J Androl 10:269–275

    CAS  PubMed  Google Scholar 

  • Pizzocaro G, Monfardini S (1984) No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. J Urol 131:677–680

    CAS  PubMed  Google Scholar 

  • Pont J, Albrecht W, Postner G et al (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14:441–448

    CAS  PubMed  Google Scholar 

  • Powles TB, Bhardwa J, Shamash J et al (2005) The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int 95:1197–1200

    PubMed  Google Scholar 

  • Puc HS, Heelan R, Mazumdar M et al (1996) Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14:454–460

    CAS  PubMed  Google Scholar 

  • Purdue MP, Devesa SS, Sigurdson AJ et al (2005) International patterns and trends in testis cancer incidence. Int J Cancer 115:822–827

    CAS  PubMed  Google Scholar 

  • Rabbani F, Sheinfeld J, Farivar-Mohseni H et al (2001) Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 19:2020–2025

    CAS  PubMed  Google Scholar 

  • Raina V, Singh SP, Kamble N et al (1993) Brain metastasis as the site of relapse in germ cell tumor of testis. Cancer 72:2182–2185

    CAS  PubMed  Google Scholar 

  • Rajpert-de Meyts E, Hoei-Hansen CE (2007) From gonocytes to testicular cancer: the role of impaired gonadal development. Ann N Y Acad Sci 1120:168–180

    PubMed  Google Scholar 

  • Ravi R, Ong J, Oliver RT et al (1999) The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 83:649–653

    CAS  PubMed  Google Scholar 

  • Rayson D, Burch PA, Richardson RL (1998) Sarcoidosis and testicular carcinoma. Cancer 83:337–343

    CAS  PubMed  Google Scholar 

  • Read G, Stenning SP, Cullen MH et al (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 10:1762–1768

    CAS  PubMed  Google Scholar 

  • Reiter WJ, Brodowicz T, Alavi S et al (2001) Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19:101–104

    CAS  PubMed  Google Scholar 

  • Richiardi L, Akre O, Montgomery SM et al (2004) Fecundity and twinning rates as measures of fertility before diagnosis of germ-cell testicular cancer. J Natl Cancer Inst 96:145–147

    PubMed  Google Scholar 

  • Richiardi L, Scelo G, Boffetta P et al (2007) Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 120:623–631

    CAS  PubMed  Google Scholar 

  • Richie JP (1990) Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 144:1160–1163

    CAS  PubMed  Google Scholar 

  • Richie JP, Kantoff PW (1991) Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 9:1393–1396

    CAS  PubMed  Google Scholar 

  • Risk MC, Foster RS (2011) Postchemotherapy retroperitoneal lymph node dissection for testis cancer. Expert Rev Anticancer Ther 11:95–106

    Google Scholar 

  • Roeleveld TA, Horenblas S, Meinhardt W et al (2001) Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol 166:2166–2170

    CAS  PubMed  Google Scholar 

  • Ronnen EA, Kondagunta GV, Bacik J et al (2005) Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol 23:6999–7004

    PubMed  Google Scholar 

  • Rossen PB, Pedersen AF, Zachariae R et al (2009) Health-related quality of life in long-term survivors of testicular cancer. J Clin Oncol 27:5993–5999

    PubMed  Google Scholar 

  • Rustin GJ, Mead GM, Stenning SP et al (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197—the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25:1310–1315

    PubMed  Google Scholar 

  • Salvati M, Piccirilli M, Raco A et al (2006) Brain metastasis from non-seminomatous germ cell tumors of the testis: indications for aggressive treatment. Neurosurg Rev 29:130–137

    PubMed  Google Scholar 

  • Saxman SB, Nichols CR, Foster RS et al (1996) The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers. J Urol 155:587–589

    CAS  PubMed  Google Scholar 

  • Saxman SB, Finch D, Gonin R et al (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 16:702–706

    CAS  PubMed  Google Scholar 

  • Schmelz HU, Port M, Stockinger M et al (2010) Testis cancer cells have a genetic determination for a high sensitivity to apoptosis inducing stimuli. Urol Oncol 28:49–58

    CAS  PubMed  Google Scholar 

  • Schmoll HJ, Jordan K, Huddart R et al (2009a) Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:iv89–iv96

    Google Scholar 

  • Schmoll HJ, Jordan K, Huddart R et al (2009b) Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):83–88

    PubMed  Google Scholar 

  • Scholz M, Zehender M, Thalmann GN et al (2002) Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol 13:121–124

    CAS  PubMed  Google Scholar 

  • Schwarzman MI, Russo P, Bosl GJ et al (1989) Hormone-secreting metastatic interstitial cell tumor of the testis. J Urol 141:620–622

    CAS  PubMed  Google Scholar 

  • Scully RE (1970) Gonadoblastoma: a review of 74 cases. Cancer 25:1340–1356

    CAS  PubMed  Google Scholar 

  • Sella A, el Naggar A, Ro JY et al (1991) Evidence of malignant features in histologically mature teratoma. J Urol 146:1025–1028

    CAS  PubMed  Google Scholar 

  • Shahidi M, Norman AR, Dearnaley DP et al (2002) Late recurrence in 1263 men with testicular germ cell tumors: multivariate analysis of risk factors and implications for management. Cancer 95:520–530

    PubMed  Google Scholar 

  • Sharir S, Jewett MA, Sturgeon JF et al (1999) Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol. J Urol 161:472–475; discussion 475–476

    CAS  PubMed  Google Scholar 

  • Sharp DS, Carver BS, Eggener SE et al (2008) Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 26:5524–5529

    PubMed Central  PubMed  Google Scholar 

  • Sheinfeld J (1994) Nonseminomatous germ cell tumors of the testis: current concepts and controversies. Urology 44:2–14

    CAS  PubMed  Google Scholar 

  • Sheinfeld J (2003) Risks of the uncontrolled retroperitoneum. Ann Surg Oncol 10:100–101

    PubMed  Google Scholar 

  • Sheinfeld J, Motzer RJ (2008) Stage I testicular cancer management and necessity for surgical expertise. J Clin Oncol 26:2934–2936

    PubMed  Google Scholar 

  • Sheinfeld J, Motzer RJ, Rabbani F et al (2003) Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. J Urol 170:1159–1162

    PubMed  Google Scholar 

  • Skakkebaek NE, Berthelsen JG, Muller J (1982) Carcinoma-in-situ of the undescended testis. Urol Clin North Am 9:377–385

    CAS  PubMed  Google Scholar 

  • Sobin LH, Wittekind CH (2002) UICC: TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York

    Google Scholar 

  • Socinski MA, Garnick MB, Stomper PC et al (1988) Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal disease. J Urol 140:1437–1441

    CAS  PubMed  Google Scholar 

  • Sogani PC, Perrotti M, Herr HW et al (1998) Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 159:855–858

    CAS  PubMed  Google Scholar 

  • Sonne SB, Kristensen DM, Novotny GW et al (2008) Testicular dysgenesis syndrome and the origin of carcinoma in situ testis. Int J Androl 31:275–287

    PubMed  Google Scholar 

  • Sonne SB, Almstrup K, Dalgaard M et al (2009) Analysis of gene expression profiles of microdissected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte. Cancer Res 69:5241–5250

    PubMed Central  CAS  PubMed  Google Scholar 

  • Sonneveld DJ, Sleijfer DT, Koops HS et al (1998) Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer 82:1343–1351

    CAS  PubMed  Google Scholar 

  • Sonneveld DJ, Sleijfer DT, Schrafford Koops H et al (1999) Familial testicular cancer in a single-centre population. Eur J Cancer 35:1368–1373

    CAS  PubMed  Google Scholar 

  • Spears WT, Morphis JG 2nd, Lester SG et al (1992) Brain metastases and testicular tumors: long-term survival. Int J Radiat Oncol Biol Phys 22:17–22

    CAS  PubMed  Google Scholar 

  • Spiess PE, Brown GA, Liu P et al (2006a) Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107:1483–1490

    PubMed  Google Scholar 

  • Spiess PE, Brown GA, Pisters LL et al (2006b) Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer 107:1503–1510

    PubMed  Google Scholar 

  • Spiess PE, Kassouf W, Brown GA et al (2007) Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol 177:1330–1334; discussion 1334

    PubMed  Google Scholar 

  • Steiner H, Holtl L, Wirtenberger W et al (2002) Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study. Urology 60:324–328

    PubMed  Google Scholar 

  • Stenning SP, Parkinson MC, Fisher C et al (1998) Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 83:1409–1419

    CAS  PubMed  Google Scholar 

  • Stephenson AJ, Russo P, Kaplinsky R et al (2004) Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor. J Urol 171:1474–1477

    PubMed  Google Scholar 

  • Stephenson AJ, Bosl GJ, Bajorin DF et al (2005a) Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 174:557–560

    PubMed  Google Scholar 

  • Stephenson AJ, Bosl GJ, Motzer RJ et al (2005b) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 23:2781–2788

    PubMed  Google Scholar 

  • Stephenson AJ, Bosl GJ, Motzer RJ et al (2007) Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 25:5597–5602

    PubMed  Google Scholar 

  • Stephenson AJ, Aprikian AG, Gilligan TD et al (2011) Clinical practice guidelines on the management of low-stage nonseminomatous germ cell tumors of the testis. Urology 78:S444–S455

    PubMed  Google Scholar 

  • Steyerberg EW, Keizer HJ, Fossa SD et al (1995) Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13:1177–1187

    CAS  PubMed  Google Scholar 

  • Steyerberg EW, Keizer HJ, Messemer JE et al (1997) Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor: prediction of histology. ReHiT Study Group. Cancer 79:345–355

    CAS  PubMed  Google Scholar 

  • Steyerberg EW, Gerl A, Fossa SD et al (1998) Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16:269–274

    CAS  PubMed  Google Scholar 

  • Stomper PC, Kalish LA, Garnick MB et al (1991) CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded? Radiology 180:711–714

    CAS  PubMed  Google Scholar 

  • Subramanian VS, Nguyen CT, Stephenson AJ et al (2010) Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol 28:504–509

    PubMed  Google Scholar 

  • Suzumura S, Ioka A, Nakayama T et al (2008) Hospital procedure volume and prognosis with respect to testicular cancer patients: a population-based study in Osaka, Japan. Cancer Sci 99:2260–2263

    CAS  PubMed  Google Scholar 

  • Sweeney CJ, Hermans BP, Heilman DK et al (2000) Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma—predominant testis cancer. J Clin Oncol 18:358–362

    CAS  PubMed  Google Scholar 

  • Tandstad T, Dahl O, Cohn-Cedermark G et al (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27:2122–2128

    PubMed  Google Scholar 

  • Tarin TV, Sonn G, Shinghal R (2009) Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 181:627–632; discussion 632–633

    PubMed  Google Scholar 

  • Theodore C, Terrier-Lacombe MJ, Laplanche A et al (2004) Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. Br J Cancer 90:55–59

    PubMed Central  PubMed  Google Scholar 

  • Tiffany P, Morse MJ, Bosl G et al (1986) Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. Cancer 57:978–983

    CAS  PubMed  Google Scholar 

  • Tinkle LL, Graham BS, Spillane TJ et al (2001) Testicular choriocarcinoma metastatic to the skin: an additional case and literature review. Cutis 67:117–120

    CAS  PubMed  Google Scholar 

  • Tjan-Heijnen VC, Vlasveld LT, Pernet FP et al (1998) Coincidence of seminoma and sarcoidosis: a myth or fact? Ann Oncol 9:321–325

    CAS  PubMed  Google Scholar 

  • Tognoni PG, Foster RS, McGraw P et al (1998) Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology. J Urol 159:1833–1835

    CAS  PubMed  Google Scholar 

  • Toner GC, Panicek DM, Heelan RT et al (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8:1683–1694

    CAS  PubMed  Google Scholar 

  • Toner GC, Stockler MR, Boyer MJ et al (2001) Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357:739–745

    CAS  PubMed  Google Scholar 

  • Travis LB, Fossa SD, Schonfeld SJ et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365

    PubMed  Google Scholar 

  • Ulbright TM (2004) Testicular and paratesticular tumors. In: Mills SE, Greenson JK, Oberman HA et al (eds) Sternberg’s diagnostic surgical pathology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 2168–2190

    Google Scholar 

  • Ulbright TM (2005) Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol 18(Suppl 2):S61–S79

    PubMed  Google Scholar 

  • Ulbright TM, Young RH (2008) Metastatic carcinoma to the testis: a clinicopathologic analysis of 26 nonincidental cases with emphasis on deceptive features. Am J Surg Pathol 32:1683–1693

    PubMed  Google Scholar 

  • van den Belt-Dusebout AW, de Wit R, Gietema JA et al (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370–4378

    PubMed  Google Scholar 

  • van Dijk MR, Steyerberg EW, Habbema JD (2006) Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur J Cancer 42:820–826

    PubMed  Google Scholar 

  • Vergouwe Y, Steyerberg EW, Foster RS et al (2001) Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. J Urol 165:84–88; discussion 88

    CAS  PubMed  Google Scholar 

  • Vergouwe Y, Steyerberg EW, Eijkemans MJ et al (2003) Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 21:4092–4099

    PubMed  Google Scholar 

  • Verhoeven R, Houterman S, Kiemeney B et al (2008) Testicular cancer: marked birth cohort effects on incidence and a decline in mortality in southern Netherlands since 1970. Int J Cancer 122:639–642

    CAS  PubMed  Google Scholar 

  • Vogelzang NJ, Fraley EE, Lange PH et al (1983) Stage II nonseminomatous testicular cancer: a 10-year experience. J Clin Oncol 1:171–178

    CAS  PubMed  Google Scholar 

  • von der Maase H, Specht L, Jacobsen GK et al (1993) Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 29A:1931–1934

    PubMed  Google Scholar 

  • von Eyben FE, Jacobsen GK, Rorth M et al (2004) Microinvasive germ cell tumour (MGCT) adjacent to testicular germ cell tumours. Histopathology 44:547–554

    Google Scholar 

  • Vuky J, Tickoo SK, Sheinfeld J et al (2002) Salvage chemotherapy for patients with advanced pure seminoma. J Clin Oncol 20:297–301

    CAS  PubMed  Google Scholar 

  • Warde P, Gospodarowicz MK, Panzarella T et al (1995) Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 13:2255–2262

    CAS  PubMed  Google Scholar 

  • Warde P, Specht L, Horwich A et al (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20:4448–4452

    PubMed  Google Scholar 

  • Warde P, Gospodarowicz M, Panzarella T et al (2005) Outcome in stage I seminoma managed by radiation therapy and surveillance. J Urol 196(Suppl 4):[abstract 719]

    Google Scholar 

  • Weissbach L, Bussar-Maatz R, Flechtner H et al (2000) RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 37:582–594

    CAS  PubMed  Google Scholar 

  • Westergaard T, Olsen JH, Frisch M et al (1996) Cancer risk in fathers and brothers of testicular cancer patients in Denmark: a population-based study. Int J Cancer 66:627–631

    CAS  PubMed  Google Scholar 

  • Williams SD, Birch R, Einhorn LH et al (1987a) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435–1440

    CAS  PubMed  Google Scholar 

  • Williams SD, Stablein DM, Einhorn LH et al (1987b) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433–1438

    CAS  PubMed  Google Scholar 

  • Williams DH, Karpman E, Sander JC et al (2009a) Pretreatment semen parameters in men with cancer. J Urol 181:736–740

    PubMed  Google Scholar 

  • Williams SB, McDermott DW, Dock W et al (2009b) Retroperitoneal lymph node dissection in patients with high risk testicular cancer. J Urol 181:2097–2101; discussion 2101–2102

    PubMed  Google Scholar 

  • Wood HM, Elder JS (2009) Cryptorchidism and testicular cancer: separating fact from fiction. J Urol 181:452–461

    PubMed  Google Scholar 

  • Wood DP Jr, Herr HW, Motzer RJ et al (1992) Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 70:2354–2357

    PubMed  Google Scholar 

  • Younger C, Ulbright TM, Zhang S et al (2003) Molecular evidence supporting the neoplastic nature of some epidermoid cysts of the testis. Arch Pathol Lab Med 127:858–860

    PubMed  Google Scholar 

  • Zagars GK, Pollack A (2001) Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 51:643–649

    CAS  PubMed  Google Scholar 

  • Zagars GK, Ballo MT, Lee AK et al (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22:640–647

    PubMed  Google Scholar 

  • Zuniga A, Kakiashvili D, Jewett MA (2009) Surveillance in stage I nonseminomatous germ cell tumours of the testis. BJU Int 104:1351–1356

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University Federico II of Naples, Naples, Italy

    Alessandro Palmieri, Paolo Verze & M. Franco

Authors
  1. Alessandro Palmieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Verze
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandro Palmieri .

Editor information

Editors and Affiliations

  1. Urology, University of Naples AOU Federico II, Naples, Italy

    Vincenzo Mirone

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Palmieri, A., Verze, P., Franco, M. (2015). Testicular Cancer. In: Mirone, V. (eds) Clinical Uro-Andrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45018-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45018-5_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45017-8

  • Online ISBN: 978-3-662-45018-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation